Author’s response to reviews

Title: Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin+S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy

Authors:

Hiroshi Saeki (h-saeki@surg2.med.kyushu-u.ac.jp)
Yasunori Emi (emi-y@saiseikai-hp.chuo.fukuoka.jp)
Eiji Oki (okieiji@surg2.med.kyushu-u.ac.jp)
Shoji Tokunaga (toksan@med.kyushu-u.ac.jp)
Yoshihiro Kakeji (kakeji@med.kobe-u.ac.jp)
Yoshito Akagi (yoshisg@med.kurume-u.ac.jp)
Hideo Baba (hdobaba@kumamoto-u.ac.jp)
Eishi Baba (e-baba@intmed1.med.kyushu-u.ac.jp)
Yoshihiko Maehara (maehara@surg2.med.kyushu-u.ac.jp)

Version: 1  Date: 06 Sep 2016

Author’s response to reviews:

REPLY FORM

MS entitled "A phase II clinical trial (KSCC1501A) examining oxaliplatin+S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy" by Saeki et al.

To the Editor:

Thank you very much for your constructive comments and for your time in reviewing our manuscript. Based on your comments, we revised our manuscript as follows:
Editor(s)' Comments to Author:

1. Ethical and Funding Approval Documentation:

Before we can proceed with your submission, can you please forward copies of all ethical approval and funding approval for our records. These documents should be sent as email attachments to the following email address, BMCeriesEditorial@biomedcentral.com. Please DO NOT upload these documents as additional files in the submission system. If your documents are not in English, please could you provide translated versions of the relevant parts. These should be endorsed and signed by a contactable person at the institution. Please also include the original documents. Can you please confirm in your cover letter that you have forwarded the requested documentation to BMCeriesEditorial@biomedcentral.com.

2. Declarations:

All manuscripts must contain the following sections under the heading 'Declarations':

Ethics approval and consent to participate Consent for publication Availability of data and material Competing interests Funding Authors' contributions Acknowledgements Authors' information (optional)

Please see below for details on the information to be included in these sections.

If any of the sections are not relevant to your manuscript, please include the heading and write 'Not applicable' for that section.
3. Please include email address of all authors on the title page.

Reply:

1. I have forwarded the requested documentation (Ethical and Funding Approval Documentation) to BMCeriesEditorial@biomedcentral.com.

2. Based on the comments, Ethics approval and consent to participate Consent for publication, Availability of data and material Competing interests, Funding, Authors' contributions, Acknowledgements and Authors' information were contained under the heading 'Declarations' in page 19-21 of the revised version.

3. I included email address of all authors on the title page.